Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$79.73

1.36 (1.74%)

05:23
12/07/18
12/07
05:23
12/07/18
05:23

Piper remains buyers of Alnylam following recent weakness

Alnylam Pharmaceuticals' R&D day highlighted the the transition into a commercial stage company with multiple late stage programs, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Alnylam is expanding RNAi drug discovery outside of the liver into central nervous system and cardiovascular disease, adds the analyst. He says Piper remains buyers of Alnylam on recent weakness ahead of new RNAi drug approvals and data read-outs. Tenthoff reiterates an Overweight rating on the stock with a $160 price target.

ALNY Alnylam
$79.73

1.36 (1.74%)

11/07/18
PIPR
11/07/18
NO CHANGE
Target $160
PIPR
Overweight
Alnylam weakness a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff remains a buyer of Alnylam Pharmaceuticals on weakness after the company reported initial Onpattro Q3 sales of $460,000, below his $3M estimate. The initial launch metrics and advantageous commercial profile versus Tegsedi should translate into adoption, Tenthoff tells investors in a research note. 125 patient start forms submitted as of Q3, which is not the only source of demand, could translate into $11M in further Onpattro sales over the next few quarters, says the analyst. He reiterates an Overweight rating on Alnylam shares with a $160 price target.
11/15/18
STFL
11/15/18
NO CHANGE
Target $111
STFL
Buy
Alnylam management 'exudes confidence' in TTR launch, says Stifel
After hosting a dinner with Alnylam CEO John Maraganore and the company's management, Stifel analyst Paul Matteis said management "exudes confidence" that Onpattro can penetrate a substantial portion of the diagnosed haTTR population while acknowledging that it takes a little time to convert "start forms" into paying commercial patients. Management also seems "completely at ease" ahead of the full readout of the givosiran phase 3 ENVISION data, said Matteis, who keeps a Buy rating and $111 price target on Alnylam shares.
11/27/18
LEER
11/27/18
INITIATION
Target $63
LEER
Market Perform
Alnylam initiated with a Market Perform at Leerink
Leerink analyst Mani Foroohar initiated Alnylam with a Market Perform rating and a price target of $63.
11/27/18
LEER
11/27/18
INITIATION
LEER
Leerink initiates select Genetic Medicine names on increasing regulatory clarity
Leerink analyst Mani Foroohar initiated select Genetic Medicine stocks, stating that the field is "is rich with companies developing drugs" to treat rare diseases and that he is increasingly more bullish on "innovation velocity and increasing regulatory clarity in the sector. Based on his "balanced view of pricing dynamics", the analyst issues an Outperform rating on Wave Life Sciences (WVE), Rocket Pharmaceuticals (RCKT), Intellia Therapeutics (NTLA), Eidos Therapeutics (EIDX), Dicerna (DRNA) and Bluebird Bio (BLUE). The analyst likes Wave Life Sciences as a pure play on Oligotherapeutics and its stereopure chemistry platform as a differentiated approach to oligo drug design. Foroohar is positive on Rocket Pharma's lead assets in gene therapies for Fanconi Anemia and Leukocyte Adhesion Deficiency-I "which will likely be the company's first potential approved product." The analyst is positive on Intellia Therapeutics' "robust balance sheet to support development, trading at a material discount to closest comps peers". For Eidos, the analyst cites the prospects of its drug candidate for TTR amyloidosis currently in a placebo-controlled Phase 2 study that may offer a competitive profile relative to Pfizer's (PFE) tafamidis. For Dicerna, Foroohar notes that its DCR-PHXC "is an RNAi therapeutic that targets lactate dehydrogenase A for the treatment of all subtypes of Primary Hyperoxaluria vs. competitor Alnylam's (ALNY) lumasiran, which only treats PH Type 1. For Bluebird Bio, the analyst is positive on its position as a "leader in ex vivo gene therapy, with four programs with visibility towards near-term regulatory approval". Foroohar initiates Avrobio (AVRO), Alnylam (ALNY), and Ionis Pharmaceuticals (IONS) with Market Perform rating based on competitive launches for their products along with "mixed" early signs of their results. The analyst also rates Regenxbio (RGNX) at underperform, saying that its "current valuation more than accounts for robust royalty streams from sales in spinal muscular atrophy" and other partnered assets.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

, GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

19:08
03/19/19
03/19
19:08
03/19/19
19:08
Periodicals
Google offers Android, product ad concessions for Europe, WSJ says »

Google intends to ask all…

GOOG

Alphabet

$1,199.71

16.05 (1.36%)

GOOGL

Alphabet Class A

$1,203.13

15.04 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

, SCS

Steelcase

$17.49

-0.115 (-0.65%)

19:06
03/19/19
03/19
19:06
03/19/19
19:06
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

SMAR

Smartsheet

$43.51

-0.16 (-0.37%)

SCS

Steelcase

$17.49

-0.115 (-0.65%)

AUPH

Aurinia Pharmaceuticals

$6.40

0.13 (2.07%)

NVRO

Nevro

$44.76

0.37 (0.83%)

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

TME

Tencent Music

$18.65

-0.48 (-2.51%)

WPRT

Westport

$1.50

(0.00%)

AIR

AAR Corp.

$35.10

(0.00%)

FDX

FedEx

$181.50

-0.92 (-0.50%)

FNV

Franco-Nevada

$75.64

0.035 (0.05%)

PRNB

Principia Biopharma

$36.88

0.48 (1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 01

    Apr

  • 02

    Apr

  • 05

    Apr

  • 14

    May

  • 28

    May

  • 24

    Jun

  • 26

    Jun

LGIH

LGI Homes

$54.89

-2.27 (-3.97%)

19:02
03/19/19
03/19
19:02
03/19/19
19:02
Hot Stocks
LGI Homes announces new community in Las Vegas »

LGI Homes, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

19:01
03/19/19
03/19
19:01
03/19/19
19:01
Hot Stocks
Sage says Zulresso approval represents 'game-changing approach' to PPD »

Sage Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

QTRX

Quanterix

$24.59

-0.01 (-0.04%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Quanterix »

Quanterix files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIHS

Senmiao Technology

$4.71

-0.275 (-5.52%)

18:55
03/19/19
03/19
18:55
03/19/19
18:55
Syndicate
Breaking Syndicate news story on Senmiao Technology »

Senmiao Technology files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:54
03/19/19
03/19
18:54
03/19/19
18:54
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

PULM

Pulmatrix

$1.70

-0.09 (-5.03%)

18:53
03/19/19
03/19
18:53
03/19/19
18:53
Syndicate
Breaking Syndicate news story on Pulmatrix »

Pulmatrix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

SIEN

Sientra

$8.81

-0.4 (-4.34%)

18:51
03/19/19
03/19
18:51
03/19/19
18:51
Recommendations
Sientra analyst commentary  »

Sientra implied costs to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INVH

Invitation Homes

$23.31

-0.23 (-0.98%)

18:50
03/19/19
03/19
18:50
03/19/19
18:50
Syndicate
Breaking Syndicate news story on Invitation Homes »

Invitation Homes files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:45
03/19/19
03/19
18:45
03/19/19
18:45
Hot Stocks
FedEx CEO: Domestic business is pretty good »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

LYFT

Lyft

$0.00

(0.00%)

18:41
03/19/19
03/19
18:41
03/19/19
18:41
Periodicals
Lyft IPO oversubscribed so far, Reuters reports »

Lyft's IPO is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 21

    Mar

  • 21

    Mar

  • 22

    Mar

  • 25

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

NSTG

NanoString

$24.27

-3.03 (-11.10%)

18:37
03/19/19
03/19
18:37
03/19/19
18:37
Syndicate
NanoString 4.5M share Secondary priced at $23.00 »

JPMorgan, UBS and Cowen…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

GLD

SPDR Gold Shares

$123.39

0.35 (0.28%)

18:37
03/19/19
03/19
18:37
03/19/19
18:37
Hot Stocks
Breaking Hot Stocks news story on SPDR Gold Shares »

SPDR Gold Shares holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCLH

Norwegian Cruise Line

$56.11

-0.03 (-0.05%)

18:33
03/19/19
03/19
18:33
03/19/19
18:33
Hot Stocks
Norwegian Cruise Line CEO: There is no recession »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

NTNX

Nutanix

$38.78

0.425 (1.11%)

18:23
03/19/19
03/19
18:23
03/19/19
18:23
Hot Stocks
Nutanix CEO: Our churn is really small »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

  • 04

    Apr

  • 09

    Jul

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:20
03/19/19
03/19
18:20
03/19/19
18:20
Earnings
FedEx says started FY19 expecting revenue to rise $6B, but will see $4.5B »

This implies FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

SAGE

Sage Therapeutics

$156.08

-0.89 (-0.57%)

18:04
03/19/19
03/19
18:04
03/19/19
18:04
Hot Stocks
FDA approves Sage Therapeutics' Zulresso in PPD treatment »

The FDA approved Zulresso…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

18:02
03/19/19
03/19
18:02
03/19/19
18:02
Hot Stocks
FedEx says reviewing capital expense plan for FY20 »

Sees FY19 effective tax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

BAYRY

Bayer

$0.00

(0.00%)

17:58
03/19/19
03/19
17:58
03/19/19
17:58
Periodicals
Bayer to face liability in second phase of Roundup trial, Bloomberg says »

Bayer has lost the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

FDX

FedEx

$181.50

-0.92 (-0.50%)

17:57
03/19/19
03/19
17:57
03/19/19
17:57
Hot Stocks
FedEx says higher operating costs likely to continue to impact results »

Says will know about…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

GPRO

GoPro

$6.26

0.005 (0.08%)

17:51
03/19/19
03/19
17:51
03/19/19
17:51
Periodicals
GoPro rival China's Insta360 plans 2020 IPO, CNBC says »

GoPro rival Insta360,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$181.50

-0.92 (-0.50%)

, AMZN

Amazon.com

$1,762.45

20.45 (1.17%)

17:47
03/19/19
03/19
17:47
03/19/19
17:47
Hot Stocks
FedEx Co-CEO Carter says Amazon not a threat to future growth »

Says well placed to take…

FDX

FedEx

$181.50

-0.92 (-0.50%)

AMZN

Amazon.com

$1,762.45

20.45 (1.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

  • 26

    Mar

  • 01

    Apr

  • 02

    Apr

  • 04

    Apr

FRBA

First Bank

$11.41

-0.14 (-1.21%)

17:46
03/19/19
03/19
17:46
03/19/19
17:46
Hot Stocks
First Bank to acquire Grand Bank for $19.4M »

First Bank and Grand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$72.00

0.13 (0.18%)

17:42
03/19/19
03/19
17:42
03/19/19
17:42
Hot Stocks
Cognizant President Rajeev Mehta sells over $1.4M in company shares »

Cognizant President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.